Cancer Research and Treatment

Lung cancer

Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase–Low Squamous Cell Lung Cancer: Mihong Choi, Heung Tae Kim, Ji-Youn Han, Geon Kook Lee, Soo-Hyun Lee, Kun Young Lim, Jungnam Joo, Hye Jin Won, Jin Soo Lee, Youngjoo Lee; Cancer Res Treat. 2021;53(1):87-92. Published online August 13, 2020; DOI: https://doi.org/10.4143/crt.2020.741

Abstract PDF Supplementary Material PubReader ePub

Purpose
Squamous cell carcinomas (SqCC) of the lung often express high levels of thymidylate synthase (TS), which is associated with primary resistance to pemetrexed. We explored the efficacy of pemetrexed in a selected population of patients with lung SqCC with low TS expression.
Materials and Methods
In this single-arm phase II trial, we enrolled 32 previously-treated patients with advanced lung SqCC exhibiting low immunohistochemical staining for TS (i.e., in 10% or less of tumor cells). The primary endpoint was 12-week progression-free survival (PFS) rate.
Results
Of 32 patients, eight patients (25%) had an Eastern Cooperative Oncology Group performance status of 2, and seven patients (22%) had previously received three or more lines of chemotherapy. The disease control rate from pemetrexed treatment was 30%, and no objective response was observed. The 12-week PFS rate was 24.5% (95% confidence interval [CI], 13.0 to 46.1). Median PFS was 1.3 months (95% CI, 1.3 to 2.7), and median overall survival was 11.8 months (95% CI, 8.1 to not applicable). Most of adverse events were grade 1 or 2.
Conclusion
Pemetrexed demonstrated modest activity as a salvage chemotherapy in patients with advanced lung SqCC with low TS expression, although its toxicity was generally manageable.

Citations

Citations to this article as recorded by

Bioengineered miR-7-5p modulates non–small cell lung cancer cell metabolism to improve therapy
Gavin M. Traber, Mei-Juan Tu, Su Guan, Neelu Batra, Ai-Ming Yu
Molecular Pharmacology.2025; 107(1): 100006. CrossRef

6,981 View
129 Download
1 Crossref

Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis: Jongheon Jung, Hyae Young Kim, Dong-Gil Kim, Seog Yun Park, A Ra Ko, Ji-Youn Han, Heung Tae Kim, Jin Soo Lee, Youngjoo Lee; Cancer Res Treat. 2021;53(1):77-86. Published online August 6, 2020; DOI: https://doi.org/10.4143/crt.2020.543

Abstract PDF Supplementary Material PubReader ePub

Purpose
Immune checkpoint inhibitors (ICI) and targeted small-molecule drugs are mainstay elements of lung cancer chemotherapy. However, they are associated with development of pneumonitis, a rare, but potentially life-threatening event. We analyzed lung cancer patients treated with ICI to evaluate the effect of sequential therapeutic administration on the incidence of pneumonitis.
Materials and Methods
In this retrospective study, 242 patients were included. Serial radiologic findings taken during and immediately after ICI treatment were reviewed. Factors that increased pneumonitis and the relationship between peri-ICI chemotherapy and the development of pneumonitis were evaluated.
Results
Pneumonitis developed in 23 patients (9.5%); severe pneumonitis (grade ≥ 3) occurred in 13 of 23 patients (56%); pneumonitis-related death occurred in six. High-dose thoracic radiation (≥ 6,000 cGy) revealed a tendency toward high risk of pneumonitis (odds ratio, 2.642; 95% confidence interval, 0.932 to 7.490; p=0.068). Among 149 patients followed for ≥ 8 weeks after the final ICI dose, more patients who received targeted agents within 8-weeks post-ICI experienced pneumonitis (3/16, 18.8%) compared with patients who received cytotoxic agents (4/54, 7.4%) or no chemotherapy (4/79, 5.1%) (p=0.162). Targeted therapy was associated with earlier-onset pneumonitis than treatment with cytotoxic agents (35 vs. 62 days post-ICI, p=0.007); the resulting pneumonitis was more severe (grade ≥ 3, 100% vs. 0%, p=0.031).
Conclusion
Sequential administration of small-molecule targeted agents immediately after ICI may increase the risk of severe pneumonitis. The sequence of chemotherapy regimens that include ICI and targeted agents should be carefully planned to reduce the risk of pneumonitis in lung cancer patients.

Citations

Citations to this article as recorded by

Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature
Anne-Laure Désage, Michael Duruisseaux, Claire Lafitte, Sophie Bayle-Bleuez, Christos Chouaid, Pierre Fournel, Thomas Pierret
Cancer Treatment Reviews.2024; 129: 102805. CrossRef
Deep learning for predicting the risk of immune checkpoint inhibitor-related pneumonitis in lung cancer
M. Cheng, R. Lin, N. Bai, Y. Zhang, H. Wang, M. Guo, X. Duan, J. Zheng, Z. Qiu, Y. Zhao
Clinical Radiology.2023; 78(5): e377. CrossRef
Evaluating Pneumonitis Incidence in Patients with Non–small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data
Qi Liu, Chenan Zhang, Yue Huang, Ruihao Huang, Shiew-Mei Huang, Erin Larkins, Liza Stapleford, Donna R. Rivera, Paul G. Kluetz, Shenggang Wang, Hao Zhu, James Weese, Elizabeth Cromartie, Mahder Teka, Sheetal Walters, Frank Wolf, Thomas D. Brown
Cancer Research Communications.2023; 3(2): 258. CrossRef
Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy
Yi-Pu Zhao, Yong Long
Current Medical Research and Opinion.2022; 38(8): 1369. CrossRef
Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
Yuxuan Hao, Xiaoye Zhang, Li Yu
Frontiers in Oncology.2022;[Epub] CrossRef
Improving Time-to-Treatment for Advanced Non-Small Cell Lung Cancer Patients through Faster Single Gene EGFR Testing Using the Idylla™ EGFR Testing Platform
Norbert Banyi, Deepu Alex, Curtis Hughesman, Kelly McNeil, Diana N. Ionescu, Carmen Ma, Stephen Yip, Barbara Melosky
Current Oncology.2022; 29(10): 7900. CrossRef
Sequential or combined immune checkpoint inhibitors and targeted therapy: Navigating uncharted waters
K. El Husseini, M. Wislez
Respiratory Medicine and Research.2021; 79: 100820. CrossRef
Multiple drugs

Reactions Weekly.2021; 1863(1): 255. CrossRef
Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway
Jeong Hun Kim, Won Suk Lee, Hye Jin Lee, Hannah Yang, Seung Joon Lee, So Jung Kong, Soyeon Je, Hyun-Jin Yang, Jongsun Jung, Jaekyung Cheon, Beodeul Kang, Hong Jae Chon, Chan Kim
OncoImmunology.2021;[Epub] CrossRef

7,916 View
202 Download
9 Web of Science
9 Crossref

Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status: Youngjoo Lee, Ji-Youn Han, Sung Ho Moon, Byung-Ho Nam, Kun Young Lim, Geon Kook Lee, Heung Tae Kim, Tak Yun, Hye Jin An, Jin Soo Lee; Cancer Res Treat. 2017;49(4):981-989. Published online January 6, 2017; DOI: https://doi.org/10.4143/crt.2016.522

Abstract PDF Supplementary Material PubReader ePub

Purpose
Concurrent chemoradiotherapy (CCRT) is the standard care for stage III non-small cell lung cancer (NSCLC) patients; however, a more effective regimen is needed to improve the outcome by better controlling occult metastases. We conducted two parallel randomized phase II studies to incorporate erlotinib or irinotecan-cisplatin (IP) into CCRT for stage III NSCLC depending on epidermal growth factor receptor (EGFR) mutation status.
Materials and Methods
Patients with EGFR-mutant tumors were randomized to receive three cycles of erlotinib first and then either CCRT with erlotinib followed by erlotinib (arm A) or CCRT with IP only (arm B). Patients with EGFR unknown or wild-type tumors were randomized to receive either three cycles of IP before (arm C) or after CCRT with IP (arm D).
Results
Seventy-three patients were screened and the study was closed early because of slow accrual after 59 patients were randomized. Overall, there were seven patients in arm A, five in arm B, 22 in arm C, and 25 in arm D. The response rate was 71.4% and 80.0% for arm A and B, and 70.0% and 73.9% for arm C and D. The median overall survival (OS) was 39.3 months versus 31.2 months for arm A and B (p=0.442), and 16.3 months versus 25.3 months for arm C and D (p=0.050). Patients with sensitive EGFR mutations had significantly longer OS than EGFR-wild patients (74.8 months vs. 25.3 months, p=0.034). There were no unexpected toxicities.
Conclusion
Combined-modality treatment by molecular diagnostics is feasible in stage III NSCLC. EGFR-mutant patients appear to be a distinct subset with longer survival.

Citations

Citations to this article as recorded by

Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
Terufumi Kato, Ignacio Casarini, Manuel Cobo, Corinne Faivre-Finn, Fiona Hegi-Johnson, Shun Lu, Mustafa Özgüroğlu, Suresh S. Ramalingam
Lung Cancer.2024; 187: 107414. CrossRef
The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC
Allison E B Chang, Andrew J Piper-Vallillo, Raymond H Mak, Michael Lanuti, Alona Muzikansky, Julia Rotow, Pasi A Jänne, Mari Mino-Kenudson, Scott Swanson, Cameron D Wright, David Kozono, Paul Marcoux, Zofia Piotrowska, Lecia V Sequist, Henning Willers
The Oncologist.2024; 29(7): 609. CrossRef
Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario
Valeria Fuorivia, Ilaria Attili, Carla Corvaja, Riccardo Asnaghi, Ambra Carnevale Schianca, Pamela Trillo Aliaga, Ester Del Signore, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis
Current Oncology.2024; 31(9): 5121. CrossRef
Comparison of treatment regimens for unresectable stage III epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer
Xin Dai, Qian Xu, Lei Sheng, Xue Zhang, Miao Huang, Song Li, Kai Huang, Jiahui Chu, Jian Wang, Jisheng Li, Yanguo Liu, Jianyuan Zhou, Shulun Nie, Lian Liu
Chinese Medical Journal.2024;[Epub] CrossRef
Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer
Jerold Loh, Jia Li Low, Manavi Sachdeva, Peter QJ Low, Rachel Su Jen Wong, Yiqing Huang, Puey Ling Chia, Ross A Soo
Expert Review of Anticancer Therapy.2023; 23(9): 913. CrossRef
Peptide-Hydrogel Nanocomposites for Anti-Cancer Drug Delivery
Farid Hajareh Haghighi, Roya Binaymotlagh, Ilaria Fratoddi, Laura Chronopoulou, Cleofe Palocci
Gels.2023; 9(12): 953. CrossRef
Nuclear accumulation of KPNA2 impacts radioresistance through positive regulation of the PLSCR1‐STAT1 loop in lung adenocarcinoma
Wei‐Chao Liao, Tsung‐Jen Lin, Yu‐Chin Liu, Yu‐Shan Wei, Guan‐Ying Chen, Hsiang‐Pu Feng, Yi‐Feng Chang, Hsin‐Tzu Chang, Chih‐Liang Wang, Hsinag‐Cheng Chi, Chun‐I Wang, Kwang‐Huei Lin, Wei‐Ting Ou Yang, Chia‐Jung Yu
Cancer Science.2022; 113(1): 205. CrossRef
Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial
Ligang Xing, Gang Wu, Luhua Wang, Jiancheng Li, Jianhua Wang, Zhiyong Yuan, Ming Chen, Yaping Xu, Xiaolong Fu, Zhengfei Zhu, You Lu, Chun Han, Tingyi Xia, Conghua Xie, Guang Li, Shenglin Ma, Bing Lu, Qin Lin, Guangying Zhu, Baolin Qu, Wanqi Zhu, Jinming Y
International Journal of Radiation Oncology*Biology*Physics.2021; 109(5): 1349. CrossRef
A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer
M. Or, B. Liu, J. Lam, S. Vinod, W. Xuan, R. Yeghiaian-Alvandi, E. Hau
Scientific Reports.2021;[Epub] CrossRef
Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?
Aruz Mesci, Theodoros Tsakiridis, Anand Swaminath
Journal of Thoracic Oncology.2021; 16(10): 1607. CrossRef
Experiences of patients with lung cancer receiving concurrent chemo-radiotherapy
Choi Eunsook, Park Sunhee
Clinical Journal of Nursing Care and Practice.2021; 5(1): 015. CrossRef
Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer
Miguel J Sotelo, José Luis García, Cesar Torres-Mattos, Héctor Milián, Carlos Carracedo, María Ángeles González-Ruiz, Xabier Mielgo-Rubio, Juan Carlos Trujillo-Reyes, Felipe Couñago
World Journal of Clinical Oncology.2021; 12(10): 912. CrossRef
PLGA nanoparticle-reinforced supramolecular peptide hydrogels for local delivery of multiple drugs with enhanced synergism
Can Wu, Chunlu Wang, Lu Sun, Keming Xu, Wenying Zhong
Soft Matter.2020; 16(46): 10528. CrossRef
Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: A systematic review and meta-analysis of single-arm trials
Ruifeng Liu, Shihong Wei, Qiuning Zhang, Xueliang Zhang, Hongtao Luo, Jinhui Tian, Yi Li, Long Ge, Xiaohu Wang
Medicine.2019; 98(29): e16427. CrossRef
Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?
Sanjal Desai, Chul Kim, Irina Veytsman
Current Oncology Reports.2019;[Epub] CrossRef

10,385 View
311 Download
14 Web of Science
15 Crossref

A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer: Tak Yun, Heung Tae Kim, Ji-Youn Han, Sung Jin Yoon, Hyae Young Kim, Byung-Ho Nam, Jin Soo Lee; Cancer Res Treat. 2016;48(2):465-472. Published online May 26, 2015; DOI: https://doi.org/10.4143/crt.2015.061

Abstract PDF PubReader ePub

Purpose
Paclitaxel (P) and gemcitabine (G) are clinically synergistic in small cell lung cancer (SCLC). We evaluated the efficacy of PG as a salvage treatment for SCLC patients whose disease progressed after a platinum-containing regimen.
Materials and Methods
Eligibility included histologically confirmed SCLC, one dimensionally measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and progressive disease after platinum-based chemotherapy. Treatment consisted of P (80 mg/m2) and G (1,000 mg/m2) on days 1 and 8 of each cycle of 21 days until disease progression.
Results
Thirty-three patients seen between December 2005 and February 2009 were selected into this study. Thirty patients (91%) had received irinotecan-platinum, and three had received etoposide-platinum. Sixteen patients (49%) had a treatment-free interval of less than 3 months. The overall response rate was 30.3% (29.4% in sensitive relapse and 31.3% in refractory relapse). The median time to progression was 12.0 weeks and median overall survival (OS) 31.0 weeks, with a 1-year OS rate of 30.3%. Toxicities were moderate and manageable with 18.2% grade (G) 4 neutropenia, 24.2% G3 thrombocytopenia, 6.1% G3 sensory neuropathy, and 3% G3 asthenia. One patient developed febrile neutropenia.
Conclusion
Second-line paclitaxel and gemcitabine were well-tolerated and moderately active in SCLC patients previously treated with platinum-based chemotherapy.

Citations

Citations to this article as recorded by

Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway
Shuxin Li, Jianyi Lv, Zhihui Li, Qiuyu Zhang, Jing Lu, Xueyun Huo, Meng Guo, Xin Liu, Changlong Li, Jinghui Wang, Hanping Shi, Li Deng, Zhenwen Chen, Xiaoyan Du
Molecular Cancer.2024;[Epub] CrossRef
Impact of Nab-Paclitaxel Plus PD-1/PD-L1 Inhibitor on Chemorefractory Relapsed Small-Cell Lung Cancer
Fengchun Mu, Bingjie Fan, Haoqian Li, Wenru Qin, Chunni Wang, Bing Zou, Linlin Wang
Future Oncology.2023; 19(19): 1367. CrossRef
Iron oxide nanoparticles induce ferroptosis via the autophagic pathway by synergistic bundling with paclitaxel
Qi Nie, Wenqing Chen, Tianmei Zhang, Shangrong Ye, Zhongyu Ren, Peng Zhang, Jian Wen
Molecular Medicine Reports.2023;[Epub] CrossRef
Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy
Zhonglin Hao, Janeesh Sekkath Veedu
Clinical Lung Cancer.2022; 23(1): 14. CrossRef
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis
Jan A. Stratmann, Radha Timalsina, Akin Atmaca, Vivian Rosery, Nikolaj Frost, Jürgen Alt, Cornelius F. Waller, Niels Reinmuth, Gernot Rohde, Felix C. Saalfeld, Aaron Becker von Rose, Fabian Acker, Lukas Aspacher, Miriam Möller, Martin Sebastian
Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef
Functionalized FcRn-targeted nanosystems for oral drug delivery: A new approach to colorectal cancer treatment
Fatima Hameedat, Nuria A. Pizarroso, Natália Teixeira, Soraia Pinto, Bruno Sarmento
European Journal of Pharmaceutical Sciences.2022; 176: 106259. CrossRef
Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data
Chengcheng Gong, Yizhao Xie, Yannan Zhao, Yi Li, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Xichun Hu, Biyun Wang
Therapeutic Advances in Drug Safety.2022;[Epub] CrossRef
Impact of Nab-Paclitaxel Plus PD-1/PD-L1 Inhibitor Versus Traditional Chemotherapy for Retreatment Small Cell Lung Cancer Patients
Fengchun Mu, Bingjie Fan, Wenru Qin, Shijiang Wang, Bing Zou, Linlin Wang
SSRN Electronic Journal .2022;[Epub] CrossRef
FcRn expression in cancer: Mechanistic basis and therapeutic opportunities
Imke Rudnik-Jansen, Kenneth A. Howard
Journal of Controlled Release.2021; 337: 248. CrossRef
Nanoparticle Albumin Bound Paclitaxel in the Third-Line Treatment of Recurrent Small Cell Lung Cancer in Real-World Practice: A Single Center Experience
Yuchao Wang, Li Li, Chunhua Xu
Technology in Cancer Research & Treatment.2021;[Epub] CrossRef
Combination therapy with carboplatin and paclitaxel for small cell lung cancer
Atsuto Mouri, Ou Yamaguchi, Sachiko Miyauchi, Ayako Shiono, Harue Utsugi, Fuyumi Nishihara, Yoshitake Murayama, Hiroshi Kagamu, Kunihiko Kobayashi
Respiratory Investigation.2019; 57(1): 34. CrossRef
Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens
Yuji Takei, Yoshifumi Takahashi, Shizuo Machida, Akiyo Taneichi, Suzuyo Takahashi, Tomomi Nagashima, Hiroyuki Morisawa, Yasushi Saga, Shigeki Matsubara, Hiroyuki Fujiwara
Journal of Obstetrics and Gynaecology Research.2017; 43(2): 358. CrossRef
Second-line treatments of small-cell lung cancers
Nathalie Baize, Isabelle Monnet, Laurent Greillier, Gilles Quere, Mallorie Kerjouan, Henri Janicot, Alain Vergnenegre, Jean Bernard Auliac, Christos Chouaid
Expert Review of Anticancer Therapy.2017; 17(11): 1033. CrossRef

12,586 View
126 Download
12 Web of Science
13 Crossref

Chemopotentiation of Fresh Acute Myelogenous Leukemic Cells by Recombinant Human Granulocyte - Macrophage Colony - Stimulating Factor ( GM-CSF ) and Methotrexate: Heung Tae Kim, Jin Seok Ahn, Eun Shil Kim, Yung Jue Bang, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1998;30(2):357-369.

Abstract PDF: No abstract available.

2,155 View
13 Download

A Case of Acute Myelogenous Leukemia during Pregnancy: Jae Gyoon Lee, Sung Hyun Yang, Heung Tae Kim; J Korean Cancer Assoc. 1997;29(3):516-521.

Abstract PDF: The incidence of acute leukemia in pregnancy is rare. The treatment of acute leukemia during pregnancy is complicated and therapeutic options must be made with each individual patient. Complete remission can now be achieved in 60 to 70% of previously untreated adults with acute myelogenous leukemia (AML). Antileukemic chemotherapy can be administered safely during the second and third trimesters. Cytarabine (ara-C) and anthracycline has not been associated with birth defect. When a pregnant woman presents with acute leukemia, chemotherapy should be recommended as vigorously as in the non- pregnant woman. We reported a case of AML during pregnancy. The patient recieved induction chemotherapy with ara-C and idarubicin. The baby was delivered at 33 weeks of gestation and had transient neutropenia. The mother received consolidation chemotherapy after achievement of complete remission.

2,522 View
21 Download

A Case of Cervical Adenocarcinoma with Pulmonary Metastasis Resembling Miliary Tuberculosis: So Hee Sohn, Nah Hae Meung, Heung Tae Kim; J Korean Cancer Assoc. 1997;29(1):176-181.

Abstract PDF: Cervical cancer is the most common gynecologic cancer, accounting for 22.2% of all cancers in Korean women and is almost of squamous cell type. The reported incidence of adenocarcinoma of the uterine cervix varies from 4 to 20% of all cervical malignancies, and have shown an increase in the percentage of adenocarcinoma. Adenocarcinoma may have a slightly poorer prognosis than squamous cell carcinoma for each stage of disease. Pulmonary metastases are observed in 2~9% of patients and correlates with stage of disease. We report a case of cervical adenocarcinoma with pulmonary metastases simulating miliary tuberculosis. These metastases was confirmed by open lung biopsy.

2,369 View
15 Download

Phase II study of 5-fluorouracil and recombinant interferon-gamma in patients with advanced colorectal cancer: Heung Tae Kim, Chang In Suh, Si Young Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1992;24(5):743-758.

Abstract PDF: No abstract available.

2,792 View
14 Download

COP-BLAM III(cyclophosphamide/vincristine/prednisolone/bleomycin/ adriamycin/procarbazine) combination chemotherapy for the treatment of intermediate and high grade non-Hodgkin's lymphoma: Keong Hae Jung, Young Iee Park, Kee Heung Lee, Young Suk Park, Chang In Suh, Won Ki Kang, Heung Tae Kim, Cheol Won Suh, Dae Seog Heo, Yung Jue Bang, Seonyang Park, Noe Kyeong Kim; J Korean Cancer Assoc. 1992;24(4):586-595.

Abstract PDF: No abstract available.

2,749 View
27 Download

Combination chemotherapy for the treatment of multiple myeloma: Hyo Jin Kim, Chang In Seo, Keun Chil Park, Heung Tae Kim, Dae Seog Heo, Yung Hue Bang, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1992;24(4):577-585.

Abstract PDF: No abstract available.

2,663 View
16 Download

Phase II trial of recombinant interferon-gamma(LBD-001) in patients with malignancies: Chang In Suh, Won Ki Kang, Heung Tae Kim, Jae Hoon Lee, Dae Seog Heo, Yung Jue Bang, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim, Young Suk Park, Keun Chil Park, Sung Rok Kim; J Korean Cancer Assoc. 1992;24(4):549-561.

Abstract PDF: No abstract available.

2,402 View
14 Download

Palliative chemotherapy of soft tissue sarcoma with adriamycin and dacarbazine(ADIC) and cyclophosphamide, vinblastine, adriamycin and dacarbazine(CYVADIC): Young Suk Park, Won Ki Kang, Chang In Suh, Heung Tae Kim, Hyo Jin Kim, Keun Chil Park, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1992;24(3):401-410.

Abstract PDF: No abstract available.

3,155 View
47 Download

Induction of antileukemic cytotoxicity from peripheral blood lymphocytes of patients with acute myeloid leukemia: Yoon Koo Kang, Dae Seog Heo, Heung Tae Kim, Won Ki Kang, Keun Chil Park, Si Young Kim, Kyung Sam Cho, Sung Rok Kim, Sang Jae Lee, Byoung Kook Kim, Jin Oh Lee, Tae Woong Kang; J Korean Cancer Assoc. 1992;24(2):195-217.

Abstract PDF: No abstract available.

2,300 View
15 Download

Treatment of intermediate-grade non-Hodgkin's lymphoma with CAMP-MOB combination chemotherapy: Chang In Suh, Heung Tae Kim, Dong Bok Shin, Jae Hoon Lee, Dae Seog Heo, Yung Jue Bang, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1992;24(1):102-108.

Abstract PDF: No abstract available.

2,584 View
16 Download

Malignant lymphomas in Korea: Heung Tae Kim, Young Hyeuk Im, Chang In Suh, Young Suk Park, Won Ki Kang, Due Seog Heo, Yung Jue Bang, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1992;24(1):92-101.

Abstract PDF: No abstract available.

2,292 View
15 Download

Bleomycin, etoposide, cisplatin(BEF) combination chemotherapy for experimental germ cell tumor: Won Ki Kang, Chang In Suh, Young Suk Park, Young Hyuk Im, Heung Tae Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1991;23(2):343-349.

Abstract PDF: No abstract available.

2,255 View
14 Download

5-fluorouracil, epirubicin, cisplatin(FEP) and 5-fluorouracil, cisplatin(FP) combination chemotherapy for advanced pancreatic carcinoma: Ki Hyeong Lee, Won Ki Kang, Chang In Suh, Young Suk Park, Heung Tae Kim, Yoon Koo Kang, Hyo Jin Kim, Dae Seog Heo, Yung Jue Bang, Yong Bum Yoon, Noe Kyeong Kim, Yong Hyun Park; J Korean Cancer Assoc. 1991;23(2):315-322.

Abstract PDF: No abstract available.

2,545 View
26 Download

5-fluorouracil and cisplatin(FP) combination chemotherapy in advanced gastric cancer patients treated previously with chemotherapy: Heung Tae Kim, Kyung Hae Jung, Won Ki Kang, Young Suk Park, Chang In Suh, Young Hyunk Im, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1991;23(2):279-290.

Abstract PDF: No abstract available.

2,592 View
14 Download

The Postoperative Adjuvant Chemotherapy with Combined 5-Fluorouracil and Mitomycin-C following curative resection for gastric Cancer: Young Suk Park, Chang In Suh, Won Ki Kang, Heung Tae Kim, Yung Jue Bang, Noe Kyeong Kim, Jae Gahb Park, Kuhn Uk Lee, Kuk Jin Choe, Soo Tae Kim; J Korean Cancer Assoc. 1989;21(2):406-413.

Abstract PDF: The postoperative adjuvant chemotherapy with 12 cycles of 5-FU and mitomycin-C has been administered in 162 patients with stage II or lll gastric adenocarcinoma after curative gastric resection. 1) After a median follow-up time of 81 months, 94/163 treated patients recurred (58%). The sites of recurrent cancer were as follows: loco-regional, 419, peritoneal, 24%, distant metastases, 26%, multiple sites, 9%. 2) The 5-year disease free survival rates were 36.8% 3) The 5-year overall survival rates were 45.0% and the median survival was 50.2 months. 4) The number of lymph nodes involvement and the T stage affected disease free and overall survival. 5) The FM regimen was well tolerated, and produced moderate bone marrow suppression, anorexia, nausea, vomiting and diarrhea.

2,558 View
16 Download

Phase 1 Trial of Recombinant Interferon Gamma ( LBD - 001 ) in Cancer Patients: Noe Kyeong Kim, Yung Jue Bang, Dae Seog Heo, Heung Tae Kim, Hyo Jin Kim, Keun Chil Park, Keun Chil Park, Dong Bok Shin, Myung Chul Lee, Byoung Kook Kim, Sang Goo Shin, Seong Hoe Park, Han Ik Cho; J Korean Cancer Assoc. 1990;22(1):86-96.

Abstract PDF: A phase I study of recombinant gamma-interferon (LBD-001) was conducted in 23 patients with advanced malignancy. The schedule was the intramuscular administration of recombinant interferon-gamma 6 consecutive days a week for 2 weeks followed by 2 weeks of rest and was repeated every 28 days. Patients were assigned to six dose levels. The maximum tolerated dose was 10.0x10(6) units/m/day and the major toxicities were flulike symptoms. After intramuscular injection, the pharmacological data fit the single compartmental modeL More than 2/3 of the dose administered was absorbed. The absorbance T 1/2 was longer with values of 247.6 minutes but interferon-gamma was cleared with a short half life of 49.9 minutes from the circulation. Antitumor effects occurred in patients with chronic myelogenous leukemia and malignant melanoma.

2,664 View
19 Download

Non - Hodgkin's Lymphoma of the Central Nervous System: Chang In Suh, Heung Tae Kim, Young Hyuk Im, Young Suk Park, Won Ki Kang, Dae Seog Heo, Yung Jue Bang, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1990;22(2):323-329.

Abstract PDF: Thirty one patients with Non-Hodgkin's lymphoma of the central nervous system (CNS) were treated at the Seoul National University Hospital between Jan. 1978 and Mar. 1989. Clinical records of these patients were analyzed in order to define disease characteristics. clinical course, and risk factors for CNS involvement Six patients had primary CNS lymphoma and twenty five patients had secondary involvement of CNS. 5.3% of non-Hodgkin's lymphoma patients had secondary CNS involvement. Patients less than 30 years of age had increased risk for CNS involvement. Patients who had stage IV lymphoma had CNS invalvement more frequently than expected but without statistical significance. Median survival time was 14 months for primary CNS lymphoma and 4 months for secondary CNS lynsphoma. Cranial irradiation and intrathecal chemotherapy prolonged the survival but standard treatment should be established.

2,883 View
18 Download

The Combined Effects of 5 - Fluorouracil and Recombinant Interferon - gamma on Human gastric Cancinoma Cell Lines: Heung Tae Kim, Jae Gahb Park, Jin Pok Kim, Seong Hoe Park, Noe Kyeong Kim; J Korean Cancer Assoc. 1990;22(3):458-476.

Abstract PDF: Stomach cancer is a leading malignant disease in many countries. Conventional combination chernotherapy approaches to advanced gastric cancer only produce paitial response and there has been no impact on patient survival from these approaches as well. Of several promising new approaches the combination of interferon (IFN) and chemotherapeutic agents are now being made to improve the effectiveness for the treatment of cancer. Preclinical studies suggested that IFN may biochemically modulate the cellular uptake or metabolism of 5-fluorouracil (5-FU) resulting in s synergistic antitumor effect. Based on these data, Wadler reparted a promising result with combina- tion of 5-FU and IFN-alpha in patients with advanced colorectal carcinoma. This study was conducted to investigate the combined effects af 5-FU and recombinant IFN- gamma at cellular level against four gastric carcinoma cell lines (SNU-1, SNU-5, SNU-16, and NCI-NB7). We used a semiautomated tetrazolium-based colorimetric (MTT) assay for cytotoxicity and an isobologram analysis to evaluate the effect of the combination. The experiment was perfor- med three times on each of the three cell lines. Only two experirnents for SNU-16 and NCI-N87 showed supraadditivity (p< 0.02). On isobologram plotted by the mean value of three experiments for each cell line, supraadditivity was suggested for only SNU-16 (p = 0.055). In conclusion, our result did not document in vitro synergy between 5-FU and IFN-gamma for gastric carcinoma cell lines but additivity within clinically achievable dose range. Because in vivo immunomodulatory effect of IFN-gamma on host is more important rather than antiproliferative effect, the combination of 5-FU and IFN gamma is expected to improve the treatment of advanced gastric cancer.

2,653 View
15 Download

Cislatin , Vincristine , Bleomycin and Methotrexate ( PVBM ) Combination Chemotherapy for Advanced Uterine Cervix Cancer: Young Hyuk Im, Kee Hyung Lee, Young Suk Park, Chang In Suh, Won Ki Kang, Hyo Jin Kim, Heung Tae Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim, Soon Beom Kang, Hyo Pyo Lee, Jin Yong Lee, Seung Wook; J Korean Cancer Assoc. 1990;22(3):505-518.

Abstract PDF: Twenty-nine patient with advanced cervix cancer were treated with a combination chemotherapy of cisplatin, vincristine, bleomycin, and methotrexate between January, 1987 and December, 1988. 1) Among 19 evaluable patients, 4 patients (20.1%) achieved complete response and 6 patients (31. 6%) achieved partial response, giving an overall response rate of 51.7%. The median duration of remission was 23 weeks in the responders. 2) The median survival of overall patients was 50 7 weeks. The median survival of the responders did not reach the median value during the follow-up period of 15-81 weeks. In contrast, the median survival of the non-responders was 30.7 weeks, which was significantly shorter than that of the responders (p<0.05). 3) The only factor influencing remission rate was the pattem of failure, and the patients with distant metastasis showed higher remission rates (p<0.01). There were no prognostic factors influencing the remission duration. The factors improving survival rates were the early stage at diagnosis (p< 0. 005), the previous history of curative operation (p<0.005), and the presence of distant metastasis (p<0.01). 4) Considerable number of patients experienced toxicities. Among these, leukopenia (50%) and thrombocytopenia (4.7%) were the main hematologic toxicities. Most patients experienced nausea, vomiting, diarrhea (89.49o), stomatitis (26 3%), and alopecia (73.7%). Neurotoxicity due to vincristine or cispatin was found in 36.896 of patients, and 2 patients showed pulmonary fibrosis due to bleomycin toxicity. In conclusion, this regimen (PVBM) seems to be effective in terms of remission rates, but did not show any additional benifits in terms of remission duration or overall survival. In addition, the large number of patients experienced considerable side effects. Based on these findings, further studies are needed to find out the new regimen which is more effective and less toxic for the patients with advanced uterine cervix cancer.

3,131 View
18 Download

Cyclophosphamide , Adriamycin and Cisplatin ( CAP ) Combination Chemotherapy for Invasive Thymoma: Young Suk Park, Young Hyuk Im, Won Ki Kang, Chang In Suh, Kee Hyung Lee, Kyung Hae Jung, Heung Tae Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1990;22(3):532-539.

Abstract PDF: Between October 1985 and January 1990, the combination chemotherapy with cyclophosphamide, adriamycin and cisplatin (CAP) has been administered in 16 patients with invasive, recurrent or metastatic thymoma. Among 14 evaluable patients, 1 patient(7%) achieved a complete response and 4 patients (29%) had a partial response. The 4 year overall survival rates were 56.7% with a median follow-up of 11.5 months. The mast frequent hematologic toxicity was leukopenia (15.9%) and nonhematologic toxicity (WHO criteria; grade II) were alopecia (80%) and nausea/vomiting (66.7%). The CAP regimen is effective and well tolerated for the treatment of invasive thymoma, and further study is needed to confirm the relative effectiveness of CAP regimen in comparison with other regimens and to find out the prognostic factors related to response rate and survival

3,318 View
38 Download

Search